Chiasma Inc (NASDAQ:CHMA) – Investment analysts at Cantor Fitzgerald upped their FY2019 earnings per share estimates for shares of Chiasma in a research report issued to clients and investors on Wednesday, November 6th. Cantor Fitzgerald analyst B. Folkes now forecasts that the biotechnology company will post earnings of ($1.08) per share for the year, up from their prior forecast of ($1.09). Cantor Fitzgerald currently has a “Buy” rating and a $18.00 target price on the stock.

Chiasma (NASDAQ:CHMA) last issued its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.20) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.01.

CHMA has been the topic of a number of other reports. ValuEngine downgraded shares of Chiasma from a “hold” rating to a “sell” rating in a report on Wednesday, October 2nd. HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of Chiasma in a report on Thursday. Zacks Investment Research downgraded shares of Chiasma from a “buy” rating to a “hold” rating in a report on Monday, October 14th. Piper Jaffray Companies began coverage on shares of Chiasma in a report on Wednesday, July 31st. They issued an “overweight” rating and a $11.00 target price on the stock. Finally, Brookline Capital Management restated a “buy” rating on shares of Chiasma in a report on Wednesday, July 24th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $12.30.

Shares of Chiasma stock opened at $5.25 on Friday. The stock has a market capitalization of $225.72 million, a PE ratio of -4.10 and a beta of 1.19. The company’s fifty day simple moving average is $5.13 and its 200-day simple moving average is $5.95. Chiasma has a 1-year low of $2.11 and a 1-year high of $9.25.

In other Chiasma news, Director Scott Minick purchased 9,818 shares of the stock in a transaction dated Tuesday, August 20th. The stock was purchased at an average price of $5.19 per share, with a total value of $50,955.42. Following the transaction, the director now owns 62,531 shares of the company’s stock, valued at $324,535.89. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Roni Mamluk sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $4.94, for a total transaction of $49,400.00. Following the completion of the sale, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $49,400. The disclosure for this sale can be found here. Over the last 90 days, insiders bought 17,268 shares of company stock worth $96,823. Insiders own 8.30% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Vivo Capital LLC purchased a new stake in shares of Chiasma in the 2nd quarter valued at $17,758,000. BlackRock Inc. boosted its holdings in Chiasma by 868.1% during the second quarter. BlackRock Inc. now owns 1,601,272 shares of the biotechnology company’s stock worth $11,962,000 after buying an additional 1,435,873 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Chiasma by 30.9% during the second quarter. Vanguard Group Inc. now owns 1,051,908 shares of the biotechnology company’s stock worth $7,858,000 after buying an additional 248,574 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Chiasma by 85.2% during the second quarter. Renaissance Technologies LLC now owns 411,883 shares of the biotechnology company’s stock worth $3,077,000 after buying an additional 189,500 shares in the last quarter. Finally, Fosun International Ltd purchased a new stake in Chiasma during the second quarter worth $923,000. Hedge funds and other institutional investors own 53.00% of the company’s stock.

Chiasma Company Profile

Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.

Read More: How to trade on quiet period expirations

Earnings History and Estimates for Chiasma (NASDAQ:CHMA)

Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.